BioCorRx AI Stock Analysis
Want to see BICX full AI Analyst Report?
BioCorRx (BICX) AI Stock Analysis
BioCorRx
(Other OTC:BICX)
The overall score of 38 reflects an extreme risk profile. The most significant factor is the company's dire financial state, marked by insolvency, a near-total revenue collapse, and consistent cash burn, which poses an existential threat. This is compounded by a persistently bearish technical trend, with the stock trading below all major moving averages. The negative P/E ratio further confirms the lack of fundamental value. The company's survival is uncertain without immediate and substantial new financing.
BioCorRx (BICX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $6.28M
- Dividend Yield
- ―
- Average Volume (3M)
- 2,897
- Price to Earnings (P/E)
- -1.7
- Beta (1Y)
- -0.03
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 3
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Care Facilities
BioCorRx Business Overview & Revenue Model
Company Description
BioCorRx Inc. (BICX), through its various operations, is dedicated to creating and delivering therapeutic solutions for individuals struggling with substance dependence and related health conditions across the United States. Among its core offerings...
How the Company Makes Money
BioCorRx’s public disclosures historically describe revenue generation tied to (a) sales of recovery- and wellness-related products and (b) service-based offerings connected to addiction treatment and related programs delivered via company initiative...
BioCorRx Financial Statement Overview
Summary
Financial health is critically poor. The company is deeply insolvent with negative equity of -$13M, TTM revenue has collapsed 86% to just $111k, and it burns ~$1.9M in cash annually. The income statement shows massive unprofitability, and the balance sheet indicates a maximum risk of financial failure.
Income Statement
8Very NegativeBalance Sheet
1Very NegativeCash Flow
5Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 111.04K | 797.24K | 7,665 | 89.16K | 213.84K | 48.27K |
| Gross Profit | 275.96K | 691.38K | 5,998 | 53.17K | 198.56K | 42.39K |
| EBITDA | -3.75M | -2.60M | -3.59M | -2.68M | -3.15M | -4.48M |
| Net Income | -2.04M | -3.44M | -5.11M | -3.77M | -4.37M | -5.80M |
Balance Sheet | ||||||
| Total Assets | 1.79M | 2.15M | 385.94K | 388.89K | 766.59K | 819.98K |
| Cash, Cash Equivalents and Short-Term Investments | 18.23K | 139.36K | 88.03K | 65.22K | 68.61K | 85.84K |
| Total Debt | 2.30M | 2.13M | 7.11M | 1.81M | 1.68M | 1.77M |
| Total Liabilities | 14.82M | 13.67M | 12.74M | 10.34M | 8.97M | 7.78M |
| Stockholders Equity | -13.02M | -11.22M | -12.12M | -9.82M | -8.08M | -6.84M |
Cash Flow | ||||||
| Free Cash Flow | -1.90M | -2.30M | -1.10M | -1.85M | -2.04M | -3.59M |
| Operating Cash Flow | -1.90M | -2.30M | -1.10M | -1.85M | -2.04M | -3.54M |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 | -50.00K |
| Financing Cash Flow | 1.63M | 2.35M | 1.12M | 1.85M | 2.02M | 3.08M |
BioCorRx Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BICX, the sentiment is Neutral. The current price of 0.21 is below the 20-day moving average (MA) of 0.21, below the 50-day MA of 0.22, and below the 200-day MA of 0.31, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 47.93 is Neutral, neither overbought nor oversold. The STOCH value of 12.28 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BICX.
BioCorRx Peers Comparison
Overall Rating
AIDX43Neutral
MNDR43Neutral
BICX38Underperform
XWEL38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 43Neutral | $2.73M | -0.27 | -387.27% | ― | ― | ― | |
| 43Neutral | $1.13M | -0.04 | -27.32% | ― | 4.47% | 92.03% | |
| 38Underperform | $6.28M | -1.66 | 26.14% | ― | ― | ― | |
| 38Underperform | $5.62M | -0.10 | 317.52% | ― | -7.58% | -30.33% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BICX | BioCorRx | 0.21 | -0.23 | -52.50% | |
| XWEL | Xwell, Inc. | 0.49 | -0.41 | -45.56% | |
| NIVF | Newgenivf Group Limited | 0.20 | -5764.40 | -100.00% | |
| MNDR | Mobile-health Network Solutions Class A | 0.96 | -9.12 | -90.47% | |
| BMGL | Basel Medical Group Ltd | 0.30 | -13.38 | -97.79% | |
| AIDX | 20/20 Biolabs, Inc. | 0.18 | -23.67 | -99.22% |
BioCorRx Corporate Events
BioCorRx Announces Board Resignation of Director DeVarney
NeutralOn August 31, 2026, BioCorRx Inc. announced that Kate Beebe DeVarney, Ph.D., resigned from her role as a member of the company’s board of directors, effective the same day. The company stated that her resignation was not due to any disagreement with...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 16, 2026
